# Metronidazole Pharmacokinetic Profile

## Basic Properties
| Property | Value | Notes |
|----------|--------|-------|
| Chemical Class | Nitroimidazole | 5-nitroimidazole derivative |
| Molecular Weight | 171.15 g/mol | Base compound |
| Active Metabolites | Hydroxy-metronidazole | 30-65% activity of parent |
| | Acetic acid metabolite | Minimal activity |
| Protein Binding | <20% | Concentration independent |

## Route-Specific Parameters
| Parameter | Oral | Intravenous | Rectal | Vaginal |
|-----------|-------|-------------|---------|----------|
| Bioavailability (F) | ~100% | 100% | 67-82% | 20-56% |
| Peak Concentration (Cmax) | 9.8-13.0 mg/L† | 18.0-26.0 mg/L† | 5.1-5.5 mg/L‡ | 1.0-2.0 mg/L‡ |
| Time to Peak (Tmax) | 0.25-4.0 h | End of infusion | 4.0-12.0 h | 8.0-24.0 h |
| AUC | 100-159 mg•h/L† | 151.0 mg•h/L† | 89.0-151.6 mg•h/L‡ | 24.0-32.4 mg•h/L‡ |

†After 500mg dose
‡After equivalent doses

## Core Pharmacokinetic Parameters
| Parameter | Value | Notes |
|-----------|--------|-------|
| Volume of Distribution (Vd) | 0.6-1.1 L/kg | Extensive tissue distribution |
| Total Body Clearance (CL) | 4.2-5.4 L/h | Primarily hepatic |
| Renal Clearance (CLr) | 0.48-0.72 L/h | ~10-15% of total clearance |
| Elimination Half-life (t½) | 6-10 h | Extended in liver disease |
| Metabolic Pathway | Hepatic oxidation | Multiple metabolites |

## Special Population Effects
| Population | PK Changes | Clinical Implications |
|------------|------------|---------------------|
| Neonates (<8 weeks) | t½: 24-75 h | Reduce dose frequency |
| Elderly | ↑ metabolite AUC | Monitor for side effects |
| Liver Disease | ↓ CL by 33-36% | Reduce dose |
| Renal Failure | No parent drug change | Metabolites accumulate |
| Critical Illness | Variable PK | Monitor response |

## Tissue Distribution
| Tissue/Fluid | Concentration Ratio* |
|--------------|---------------------|
| CSF | 0.7-1.0 |
| Saliva | 0.8-1.0 |
| Bile | 0.9-1.0 |
| Peritoneal | 0.8-1.0 |
| Vaginal | 0.5-1.0 |

*Tissue:Plasma ratio

## Drug Interactions
| Interacting Drug | Effect | Management |
|-----------------|---------|------------|
| Warfarin | ↑ anticoagulation | Monitor INR |
| Alcohol | Disulfiram-like reaction | Avoid alcohol |
| Lithium | ↑ lithium levels | Monitor levels |
| Phenytoin | ↑ phenytoin levels | Monitor levels |
| Barbiturates | ↓ metronidazole levels | Increase dose |

## Pharmacokinetic Terms and Definitions
| Term | Definition |
|------|------------|
| AUC | Area under the concentration-time curve |
| Cmax | Maximum (peak) plasma concentration |
| CL | Total body clearance |
| CLr | Renal clearance |
| CSF | Cerebrospinal fluid |
| F | Bioavailability |
| INR | International normalized ratio |
| PK | Pharmacokinetics |
| t½ | Elimination half-life |
| Tmax | Time to reach maximum concentration |
| Vd | Volume of distribution |
| ↑ | Increase |
| ↓ | Decrease |

## Clinical Considerations
- Food Effects: Minimal impact on absorption
- Dose Adjustments:
  - Hepatic impairment: Consider 50% dose reduction
  - Renal impairment: No adjustment needed for parent drug
  - Hemodialysis: Supplement post-dialysis
- Route Selection:
  - Oral preferred when available due to high bioavailability
  - IV for severe infections or NPO patients
  - Rectal/vaginal for local effects, limited systemic exposure